Clinical, Cosmetic and Investigational Dermatology (Oct 2022)
Successful Treatment Using Apixaban in a Patient on Hemodialysis with Uremic Calciphylaxis
Abstract
Moudi M Alasmari,1,2 Mona Y Alsheikh,3 Hend H Metwali2,4 1College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia; 2King Abdullah International Medical Research Centre, Jeddah, Saudi Arabia; 3School of Pharmacy, Taif University, Taif, Saudi Arabia; 4Pharmaceutical Care Department, King Abdulaziz Medical City, Ministry of National Guard - Health Affairs, Jeddah, Saudi ArabiaCorrespondence: Moudi M Alasmari, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, King Abdullah International Medical Research Centre, P. O. Box. 9515, Jeddah, 6656, Saudi Arabia, Tel +966-12- 2245000, Email [email protected]: Calciphylaxis is a rare but serious condition in which microvessel occlusion occurs within the subcutaneous adipose tissue and dermis, leading to painful lesions. End-stage renal disease requiring hemodialysis and warfarin therapy can increase the risk of calciphylaxis. In this report, we describe the evaluation and treatment of a 75-year-old female patient with warfarin-induced calciphylaxis who presented unique symptoms. The patient required intensive care unit admission due to hemodynamic instability, which was treated with inotropes and broad-spectrum intravenous antibiotics. This description of the patient’s unusual symptoms has the potential to provide insights needed to improve the diagnosis of future patients. Due to the unavailability of FDA-approved treatment for calciphylaxis, its management is based on data from observational studies and clinical experience.Keywords: calciphylaxis, case report, ischemia, meropenem, warfarin
